Assessing the effects of National Health Insurance reimbursement policy revisions for anti-osteoporotic drugs in Korean women aged 50 or older

Introduction The Korean National Health Insurance revised its reimbursement criteria to expand coverage for anti-osteoporotic drug treatments in 2011 (expanding diagnostic criteria and the coverage period for anti-osteoporotic therapy) and 2015 (including osteoporotic fracture patients regardless of bone mineral density). We examined whether the two revisions contributed to an increase in the prescription rates of anti-osteoporotic drugs in Korea. Methods We used the Health Insurance Review and Assessment Service-National Patient Sample data from 2010 through 2016. A segmented regression analysis of interrupted time series was performed to assess changes in the monthly prescription rates of anti-osteoporotic drugs among women aged 50 or older, defined as the proportion of elderly women prescribed with anti-osteoporotic drugs. Results Both the levels (i.e., abrupt jump or drop) and the trends (i.e., slope) of the prescription rates of anti-osteoporotic drugs in the general population, osteoporotic patients, and osteoporotic fracture patients showed no significant changes after the first revision. However, there was a significant increase in the trends in the general population (β = 0.0166, p = 0.0173) and in osteoporotic patients (β = 0.1128, p = 0.0157) after the second revision. Women aged 65 to 79 years were the most significantly increased group in terms of the treatment proportion after the second revision because the trend was significant after the second revision in all three study populations (β = 0.0300, 0.1212, 0.1392, respectively; p < 0.05). Conclusions Although the two revisions expanded reimbursement coverage, only the second revision on reimbursing based on osteoporotic fracture regardless of bone mineral density was associated with increasing the proportion of post-menopausal women being treated with anti-osteoporotic drugs.

[1]  G. Romero Abstract #300092: The Triglyceride Paradox in Patients Hospitalized for Acute Myocardial Infarction , 2020 .

[2]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  D. Kiel,et al.  Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  M. Bouxsein,et al.  Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. , 2019, Endocrine reviews.

[5]  L. Williams,et al.  Do reductions in out-of-pocket expenses for dual energy X-ray absorptiometry scans translate to reduced fracture incidence amongst older Australians? A population-based study , 2018, Archives of Osteoporosis.

[6]  S. Cummings,et al.  The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  Sung Jae Kim,et al.  Incidence and Seasonal Variation of Distal Radius Fractures in Korea: a Population-based Study , 2018, Journal of Korean medical science.

[8]  D. Bauer,et al.  Managing Osteoporosis in Patients on Long‐Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Soo-Hong Han,et al.  Epidemiology and Seasonal Variance of Incidence of Distal Radius Fractures , 2015 .

[10]  Tae Hyun Kim,et al.  Effects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea , 2015, BMJ Open.

[11]  Christine Y. Lu,et al.  Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. , 2014, Health policy.

[12]  G. Hawker,et al.  Impact of a change in physician reimbursement on bone mineral density testing in Ontario, Canada: a population-based study. , 2014, CMAJ open.

[13]  W. Leslie,et al.  Examining the impact of reimbursement on referral to bone density testing for older adults: 8 years of data from the Barwon Statistical Division, Australia , 2013, Archives of Osteoporosis.

[14]  Young-Kyun Lee,et al.  Epidemiology of Osteoporosis and Osteoporotic Fractures in South Korea , 2013, Endocrinology and metabolism.

[15]  M. Brandi,et al.  Epidemiology of Osteoporosis and Fragility Fractures , 2013 .

[16]  S. Cummings,et al.  The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  L. Levin,et al.  Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. , 2012, Health policy.

[18]  Y. Ha,et al.  The incidence and residual lifetime risk of osteoporosis-related fractures in Korea , 2011, Journal of Bone and Mineral Metabolism.

[19]  Chan Mi Park,et al.  Burden of osteoporosis in adults in Korea: a national health insurance database study , 2011, Journal of Bone and Mineral Metabolism.

[20]  H. Choi,et al.  Medical Service Utilization with Osteoporosis , 2010 .

[21]  Chun ChangBae,et al.  Republic of Korea Health system review , 2009 .

[22]  Shin-Yoon Kim,et al.  Treatment of Osteoporosis after Hip Fractures in Patients Older than 50 Years , 2007 .

[23]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[24]  A K Wagner,et al.  Segmented regression analysis of interrupted time series studies in medication use research , 2002, Journal of clinical pharmacy and therapeutics.

[25]  N. Ghannam,et al.  Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. , 1994, Annals of Saudi medicine.